The latest price and market reference information of Imatinib in 2025

Imatinib (Imatinib) is an oral Tyrosine kinase inhibitors (TKI) are mainly used to treat diseases such as chronic myelogenous leukemia (CML) and certain gastrointestinal stromal tumors (GIST). As one of the early approved targeted drugs in China, imatinib has been widely used in clinical applications. Its efficacy and safety have been verified by a large number of patients, making it an important option for long-term maintenance treatment of CML patients.

In the domestic market, the original imatinib drug has been approved for marketing and has been included in the medical insurance directory, providing certain reimbursement support to eligible patients. The current common specifications are 100mg*60 capsules/ boxes, and the market price is about six to seven hundred yuan. Through medical insurance reimbursement, patients' actual out-of-pocket expenses will be significantly reduced, and the economic burden of long-term medication is relatively controllable. Specific prices and reimbursement rates may vary due to regional policy differences, and patients should consult their local hospital pharmacy for the most accurate information.

For patients who wish to obtain their medications through economic channels, Indian generics offer a less expensive option. In the Indian market, the price of imatinib generic drugs with specifications of 100mg*120 tablets is about three to four hundred yuan. These generic drugs are highly consistent in ingredients and efficacy with domestic original drugs, but they should be purchased through formal channels to ensure drug quality and safety.

Overall, imatinib has certain options in both domestic and foreign markets. Domestic original drugs provide stable supply and reliable quality assurance through medical insurance reimbursement, while Indian generic drugs are more economical, but they need to be cautious in terms of purchasing channels and legality. Patients should consider their own financial situation, medical insurance policy and doctor's advice when choosing drugs to ensure long-term standardized treatment under the premise of safety.

Reference materials:https://www.drugs.com/